UOC
ARIA

UBS O'Connor’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

UBS O'Connor’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-50,000
Closed -$874K – 627
2013
Q2 		$874K Buy
+50,000
New +$886K 0.02% 385

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS O'Connor's ARIA Position: Q3 2013 in Review

UBS O'Connor sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2013, closing a stake of 50,000 shares — an estimated $874K sold.

UBS O'Connor first reported a position in ARIA in Q2 2013 and held it in 1 quarter. The position peaked at $874K in Q2 2013. 208 funds tracked by Wall St. Rank hold ARIA as of Q3 2013.

  • UBS O'Connor reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • UBS O'Connor sold 50,000 Ariad Pharmaceuticals Inc shares in Q3 2013, an estimated $874K.
  • UBS O'Connor first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • UBS O'Connor's Ariad Pharmaceuticals Inc position peaked at $874K in Q2 2013.
  • 208 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2013.

Based on UBS O'Connor's 13F filing for Q3 2013, filed 14 Nov 2013.